Growth Hormone Deficiency Clinical Trial
Official title:
Effects of Low Dose Growth Hormone (GH) Therapy on Insulin Sensitivity, Adipocyte Insulin-like Growth Factor-I (IGF-I) and IGF-I/Insulin Receptor Density and Regulation of Cortisol Metabolism in GH Deficient Adults
Study hypothesis:
Growth hormone (GH), through its generation of free 'bioavailable' insulin-like growth
factor (IGF)-I, can improve insulin sensitivity in adults with GH deficiency.
Study aims:
The purpose of this study is to determine the mechanism of how low dose GH treatment affects
the body's sensitivity to insulin actions and whether this low GH dose can affect the body's
handling of steroid hormone levels (cortisol clearance) in adults with GH deficiency.
Study design:
Men and women with confirmed GH deficiency, but not recently been on GH treatment will be
invited to participate in this study. The subjects will be assessed at the initial visit to
ascertain their suitability before further participating in the study. If suitable, an equal
number of men and women will be randomized to receive either low dose GH or placebo
injection for 3 months. Before, during and after treatment, the subjects will be assessed at
regularly with blood tests, scans and fat biopsies. At the first and final visit, testing
will include scans to measure the amount of whole body fat and fat in the stomach area,
muscle, and liver; blood tests to measure levels of cortisol, and fat tissue (taken from a
biopsy) analysis to measure the density of IGF-I in the muscle; whereas blood tests to
examine insulin sensitivity will also be collected. This study will use Genotropin and
Genotropin pen devices, and the the data will be analyzed using a computer statistical
program where the identity of the subjects will be coded to maintain confidentiality.
The study will be double-blinded. One hundred subjects will be screened for eligibility
initially, and 24 subjects will be enrolled with 12 subjects being randomized to receive the
low GH dose (0.1 mg/day) treatment and 12 subjects to receive Placebo treatment for 3
months, allowing a 10% drop-out rate. The subjects will be taught by either by the Endocrine
Nurse Specialists to self-administer the GH by subcutaneous injections using a Genotropin
pen device.
Visit 1, Initial Screening Assessment (as out-patient)
- Physical examination, weight, height, and waist circumference measurements
- Fasting blood glucose levels
Visit 2, Baseline Assessment (as in-patient)
- Physical examination, weight, height, and waist circumference measurements
- Fasting blood tests for glucose, insulin, C-peptide, free IGF-I, total IGF-I, IGF-2,
IGFBPs -1 and -3, non-esterified fatty acid and lipid profiles
- MRS, abdominal CT and DEXA scans
- One-step 3-hour hyperinsulinaemic euglycaemic clamp
- Cortisol production rates and urine cortisol collections
- Fat biopsies will be taken at the end of the assessment of cortisol production rates
Visit 3, Interim Assessment (Month 1) (as out-patient)
- Documentation of any adverse effects
- Fasting blood tests for glucose, insulin, C-peptide, free IGF-I, total IGF-I, IGF-2,
IGFBPs -1 and -3
Visit 4, Final Assessment (Month 3) (as in-patient)
- Physical examination, weight, height, and waist circumference measurements
- Fasting blood tests for glucose, insulin, C-peptide, free IGF-I, total IGF-I, IGF-2,
IGFBPs -1 and -3, non-esterified fatty acid and lipid profiles
- MRS, abdominal CT and DEXA scans
- One-step 3-hour hyperinsulinaemic euglycaemic clamp
- Cortisol production rates and urine cortisol collections
- Fat biopsies will be taken at the end of the assessment of cortisol production rates
Any extra blood remaining from the samples of blood drawn may be banked indefinitely with
confidential identifiers, and may be given to researchers in the future to examine for other
potential causes of diabetes and heart diseases in adults. These blood samples, however,
will not be used for genetic studies.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02243852 -
Effects of Growth Hormone (GH) Deficiency and Growth Hormone Replacement on Serum Fibroblast Growth Factor 21 (FGF21)
|
N/A | |
Completed |
NCT01440686 -
Safety, Pharmacokinetics and Pharmacodynamics Study of HL-032 in Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT00990340 -
Comparison of a Needle-free Injection Method With a Needle-syringe Injection Method
|
Phase 4 | |
Completed |
NCT00149708 -
Consequence of Lifetime Isolated Growth Hormone Deficiency
|
N/A | |
Completed |
NCT00235599 -
The IGFBP-3 Stimulation Test: A New Tool for the Diagnosis of Growth Hormone Deficiency in Children.
|
N/A | |
Completed |
NCT00459940 -
The Effects of TZD on Fat Metabolism and Insulin Sensitivity in GH-Replaced GHD Patients
|
N/A | |
Completed |
NCT01157793 -
A Multicentre, Randomised, Open-label, Controlled Study to Evaluate the Effects of Saizen® on Cardiac Function in Growth Hormone Deficient(GHD) Subjects During the Transition Phase From Childhood to Adulthood
|
Phase 4 | |
Completed |
NCT00004365 -
Study of Pituitary Size and Function in Familial Dwarfism of Sindh
|
N/A | |
Recruiting |
NCT00227253 -
Chromosome 18 Clinical Research Center
|
||
Recruiting |
NCT04121780 -
Growth Hormone Replacement Therapy for Retried Professional Football Players
|
Phase 2 | |
Completed |
NCT02934399 -
Dynamic Hormone Diagnostics in Endocrine Disease
|
||
Completed |
NCT01090778 -
Diurnal Variation of Exogenous Peptides (GH Puls/Jurgita I)
|
Phase 2 | |
Completed |
NCT01062529 -
Peripheral Metabolic Effects of Somatostatin
|
N/A | |
Completed |
NCT00965484 -
Genotropin Study Assessing Use of Injection Pen
|
Phase 3 | |
Completed |
NCT00616278 -
National Cooperative Growth Study in CKD
|
N/A | |
Completed |
NCT02693522 -
Evaluation of Efficacy and Safety of Recombinant Somatroipn in Patients With Growth Hormone Deficiency
|
Phase 3 | |
Recruiting |
NCT02908958 -
Clinical Study of Pegylated Somatropin to Treat Children Growth Hormone Deficiency
|
Phase 4 | |
Terminated |
NCT01243892 -
A Study to Evaluate Growth in Participants Treated With Somatropin (Nutropin) Using NuSpin Device
|
N/A | |
Withdrawn |
NCT00638287 -
Inter-Assay Growth Hormone and IGF-I Variability
|
N/A | |
Completed |
NCT00957671 -
Anterior Pituitary Hormone Replacement in Traumatic Brain Injury
|
Phase 4 |